EUVIMEDEUVIMED entdecken
Klinische StudieVergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients

Soufyan Annakib iD, Emma Di Méglio, Yona Dibert-Bekoy, Thierry Chevallier, Guilhem Roubaud, Pierre Fournel, Aline Guillot, Delphine Borchiellini, Damien Pouessel, Elouen Boughalem, Remy Delva, Philippe Barthelemy und 5 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70896 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Soufyan Annakib und 16 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, CHU Nîmes, Univ Montpellier, Nîmes, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immune Checkpoint Inhibitors, Patient Reported Outcome Measures, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centre Hospitalier Universitaire de Nîmes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) improved survival in patients with locally advanced or metastatic urothelial carcinoma (la/mUC). Patient‐reported symptoms in this context were poorly studied. The study aimed to compare symptom severity between patients and clinicians. Methodology The secondary analysis of the AMI clinical trial comparing changes in the gut microbiota in patients with la/mUC treated with pembrolizumab was conducted in nine French centers. Secondary endpoints were expected in this prospective study. Patient‐Reported Outcome‐Common Terminology Criteria for Adverse Events (PRO‐CTCAE) and CTCAE were assessed respectively by patients and clinicians before pembrolizumab initiation, and at each treatment visit until treatment cycle 12. Agreement in severity between clinicians and patients for grade ≥ 3 symptoms was calculated with Cohen's kappa coefficient. The toxicity index was generated for CTCAE and PRO‐CTCAE to assess discordance in a longitudinal manner. The Wilcoxon test was used to compare clinicians' and patients' toxicity index and symptom severity frequencies.

Results

Thirty‐nine patients were included (M/F sex ratio: 2.5) from December 2020 to March 2022. PRO‐CTCAE baseline completion rate was 77.5%. Cohen's kappa coefficient ranged from −0.017 (95% confidence interval (CI), [−0.039, 0.005]) for numbness/tingling to 0.161 (95% CI, [0.045, 0.276]) for fatigue. The patient self‐rated symptom toxicity index was > 2 for all symptoms compared to ≤ 0.62 (fatigue) when assessed by clinicians in longitudinal reporting of symptom frequency and severity with a p value < 0.001. The three most commonly reported symptoms by patients and clinicians, respectively, were: Fatigue 53.3% versus 23.4%, generalized pain 42.4% versus 16.5%, and insomnia 41.1% versus 9.5%. Symptom frequency reports between clinicians and patients were statistically different ( p < 0.009).

Conclusions

Symptom severity assessment showed discordance between patients and physicians. Clinicians reported fewer symptoms and graded them less severely than patients. PROs should be used to accurately reflect patient experience. Trial Registration ClinicalTrials.gov identifier: NCT04566029

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsPatient Reported Outcome MeasuresUrinary Bladder NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedFranceProspective StudiesSeverity of Illness Index

Stichwörter der Autor:innen

PRO‐CTCAEadverse drug eventsbladder cancerimmune checkpoint inhibitorspatient reported outcomepembrolizumab

Substanzen

Antibodies, Monoclonal, HumanizedImmune Checkpoint Inhibitorspembrolizumab

Autor:innen und Institutionen

  • Medical Oncology Department, CHU Nîmes, Univ Montpellier, Nîmes, France.
  • Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology (BESPIM), CHU Nîmes, Univ Montpellier, Nîmes, France.
  • University of Montpellier, UMR INSERM IDESP-Desbrest Institute of Epidemiology and Public, Montpellier, France.
  • Medical Oncology Department, Institut Bergonié, Bordeaux, France.
  • Medical Oncology Department, Institut de cancérologie Lucien Neuwirth, Saint-Etienne, France.
  • Medical Oncology Department, Centre Antoine Lacassagne, Université Côte D'azur, Nice, France.

ORCID-Profile: Soufyan Annakib

Förderung

  • Centre Hospitalier Universitaire de Nîmes

Zitieren

APA

Annakib, S., Di Méglio, E., Dibert-Bekoy, Y., Chevallier, T., Roubaud, G., Fournel, P., Guillot, A., Borchiellini, D., Pouessel, D., Boughalem, E., Delva, R., Barthelemy, P., Oudard, S., Thibault, C., Tosi, D., Houédé, N., & Fiteni, F. (2025). Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients. Cancer Medicine. https://doi.org/10.1002/cam4.70896

Vancouver

Annakib S, Di Méglio E, Dibert-Bekoy Y, Chevallier T, Roubaud G, Fournel P, et al. Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients. Cancer Medicine. 2025. doi:10.1002/cam4.70896

BibTeX
@article{Annakib2025,
  author = {Annakib, Soufyan and Di Méglio, Emma and Dibert-Bekoy, Yona and Chevallier, Thierry and Roubaud, Guilhem and Fournel, Pierre and Guillot, Aline and Borchiellini, Delphine and Pouessel, Damien and Boughalem, Elouen and Delva, Remy and Barthelemy, Philippe and Oudard, Stéphane and Thibault, Constance and Tosi, Diego and Houédé, Nadine and Fiteni, Frédéric},
  title = {Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70896}
}
Kostenlos starten →